<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00926016</url>
  </required_header>
  <id_info>
    <org_study_id>C.2006.152</org_study_id>
    <nct_id>NCT00926016</nct_id>
  </id_info>
  <brief_title>Pioglitazone on Viral Kinetics, Cytokines and Innate Immunity in Insulin Resistant CHC GT 1 Subjects</brief_title>
  <official_title>Assessment of the Efficacy of Pioglitazone on Viral Kinetics, Cytokines, and Innate Immunity in a Group of Insulin Resistant, Treatment Naïve, Chronic Hepatitis C, Genotype 1 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brooke Army Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Geneva Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brooke Army Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if rosiglitazone, a medicine used to treat&#xD;
      diabetes, improves response to anti-viral treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study will be to determine if an insulin sensitizing thiazolidinedione (TZD)&#xD;
      improves (1) baseline viremia, (2) enhances viral kinetics, (3) improves cytokine profiles&#xD;
      and (4) up regulates innate cellular immunity (presumably adaptive immunity is up regulated&#xD;
      as well) as measured by the bioactivity of the collected biomarkers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in baseline viremia and viral kinetics, and/or pro-inflammatory cytokines decrease, and/or markers of innate immunity are upregulated to position a more favorable response to current CHC therapy.</measure>
    <time_frame>104 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>pioglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with pioglitazone 45 mg a day for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Monitoring period without pioglitazone for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone (Actos)</intervention_name>
    <description>pioglitazone 45 mg a day</description>
    <arm_group_label>pioglitazone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HCV-Ab or HCV-RNA by PCR Positive for at least six months (to rule out acute&#xD;
             seroconversion)&#xD;
&#xD;
          -  Serum positive for HCV-RNA by PCR assay&#xD;
&#xD;
          -  Must have insulin resistance, defined as a QUICKI score &lt; 0.35. QUICKI&#xD;
&#xD;
          -  Liver biopsy consistent with CHC within 24 months prior to enrollment&#xD;
&#xD;
          -  Compensated liver disease with the following minimum hematological, biochemical, and&#xD;
             serologic criteria at the Screening Visit (WNL = within normal limits):&#xD;
&#xD;
               -  Hemoglobin values of &gt;12 gm/dL for females and &gt;13 gm/dL for males.&#xD;
&#xD;
               -  WBC &gt;3,000/ mm3&#xD;
&#xD;
               -  Neutrophil count &gt; 1,500/mm3&#xD;
&#xD;
               -  Platelets &gt;65,000/ mm3&#xD;
&#xD;
               -  Direct bilirubin, within 20% of ULN&#xD;
&#xD;
               -  Indirect bilirubin, within normal limits (WNL)&#xD;
&#xD;
               -  Albumin &gt;3gm/dL&#xD;
&#xD;
               -  Serum creatinine &lt; 20% above the ULN&#xD;
&#xD;
               -  TSH WNL&#xD;
&#xD;
               -  Alpha fetoprotein value &lt; 100 ng/mL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior interferon based therapy&#xD;
&#xD;
          -  Use of insulin&#xD;
&#xD;
          -  Fasting glucose levels &gt; 200 mg/dl&#xD;
&#xD;
          -  Women who are pregnant or breast-feeding&#xD;
&#xD;
          -  No other thiazolidinedione after liver biopsy and/or during the entire study (&#xD;
&#xD;
          -  Hepatitis C of non-genotype 1&#xD;
&#xD;
          -  Suspected hypersensitivity to pioglitazone&#xD;
&#xD;
          -  Any cause for liver disease other than chronic hepatitis C, insulin resistance, or&#xD;
             NAFLD, including but not limited to:&#xD;
&#xD;
               -  Hemochromatosis&#xD;
&#xD;
               -  Alpha-1 antitrypsin deficiency&#xD;
&#xD;
               -  Co-infection with HBV&#xD;
&#xD;
               -  Wilson's disease&#xD;
&#xD;
               -  Autoimmune hepatitis&#xD;
&#xD;
               -  Significant alcohol use&#xD;
&#xD;
               -  Drug-related liver disease&#xD;
&#xD;
          -  Any condition that would prevent the subject from having a liver biopsy.&#xD;
&#xD;
          -  Hemoglobinopathies that could potentially compromise patient safety&#xD;
&#xD;
          -  Evidence of advanced liver disease such as history or presence of ascites, bleeding&#xD;
             varices, spontaneous encephalopathy.&#xD;
&#xD;
          -  Participants with organ transplants other than cornea and hair transplant.&#xD;
&#xD;
          -  Any known preexisting medical condition that could interfere with the subject's&#xD;
             participation in and completion of the protocol such as:&#xD;
&#xD;
               -  Preexisting psychiatric condition, especially severe depression, or a history of&#xD;
                  severe psychiatric disorder, such as major psychoses, suicidal ideation and/or&#xD;
                  suicidal attempt are excluded&#xD;
&#xD;
               -  Substance abuse, such as alcohol, IV drugs and inhaled drugs&#xD;
&#xD;
               -  Alcohol consumption is to be strongly discouraged&#xD;
&#xD;
               -  Seizure disorders not controlled with medication&#xD;
&#xD;
               -  Significant cardiovascular dysfunction within the past 12 months&#xD;
&#xD;
               -  Chronic pulmonary disease with documented pulmonary hypertension&#xD;
&#xD;
               -  Immunologically mediated disease [e.g., inflammatory bowel disease (Crohn's&#xD;
                  disease, ulcerative colitis)], rheumatoid arthritis, idiopathic thrombocytopenia&#xD;
                  purpura, systemic lupus erythematosis, autoimmune hemolytic anemia, scleroderma,&#xD;
                  severe psoriasis, clinical cryoglobulinemia with vasculitis&#xD;
&#xD;
          -  Any medical condition requiring, or likely to require, chronic systemic administration&#xD;
             of steroids during the course of the study&#xD;
&#xD;
          -  Evidence of an active or suspected cancer or a history of malignancy where the risk of&#xD;
             reoccurrence is ≥ 20% within two years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen A Harrison, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brooke Army Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brooke Army Medical Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>June 22, 2009</study_first_submitted>
  <study_first_submitted_qc>June 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2009</study_first_posted>
  <last_update_submitted>February 13, 2012</last_update_submitted>
  <last_update_submitted_qc>February 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brooke Army Medical Center</investigator_affiliation>
    <investigator_full_name>Stephen A Harrison</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

